Understanding the pharmacogenetic approach to warfarin dosing

Heart Failure Reviews

Volumn 15, Issue 3, 2010, Pages 239-248

  Glurich, Ingrid ^a   Burmester, James K ^a   Caldwell, Michael D ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Adverse drug events (ADE); Anticoagulation therapy; CYP2C9; CYP4F2; VKORC1; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C9; DABIGATRAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG UTILIZATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HUMAN; PHARMACOGENETICS; PRIMARY PREVENTION; REVIEW; STROKE; THROMBOEMBOLISM; ALGORITHM; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; GENETICS; MORTALITY;

ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; HEMORRHAGE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 77954629207     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9115-9     Document Type: Review

References (52)

1. Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167:1414-1419. doi:10.1001/archinte.167.13.1414 (Pubitemid 47052441)
2. Horton JD, Bushwick BM (1999) Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician 59:635-646
3. Centers for Disease Control, and Prevention (CDC) (2007) Prevalence of stroke-United States, 2005. MMWR Morb Mortal Wkly Rep 56:469-474
4. Evans A, Davis S, Kilpatrick C, Gerraty R, Campbell D, Greenberg P (2002) The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci 9:268-272. doi:10.1054/jocn.2001.1018
5. Garrett AD (2007) New oral anticoagulants under study. In: Pharmacy Times, May, p 49. http://www.pharmacytimes.com/issues/articles/2007-05-4655.asp. Accessed 13 May 2008
6. Johnson LA (2007) DNA tests to determine warfarin dose. In: US PHARxMD, 13 January. http://www.uspharmd.com/2007/2007-01-13.html. Accessed 13 May 2008.
7. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D et al (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 118:511-520
8. Hylek EM, Singer DE (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897-902
9. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34. doi:10.1007/s00439-006-0260-8 (Pubitemid 46421137)
10. Suttie JW (1985) Vitamin K-dependent carboxylase. Annu Rev Biochem 54:459-477. doi:10.1146/annurev.bi.54.070185.002331
11. Berkner KL (2005) The vitamin K-dependent carboxylase. Annu Rev Nutr 25:127-149. doi:10.1146/annurev.nutr.25.050304.092713 (Pubitemid 41208997)
12. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T et al (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59. doi:10.1021/tx00025a009
13. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin. Blood 105:645-649. doi:10.1182/blood-2004-06-2111 (Pubitemid 40070748)
14. Linder MW, Looney S, Adams JE 3rd, Johnson N, Antonino-Green D, Lacefield N et al (2002) Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 14:227-232. doi:10.1023/A:1025052827305 (Pubitemid 37069306)
15. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710. doi:10.1067/mcp.2002.129321 (Pubitemid 36021009)
16. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG (2000) Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128:281-285. doi:10.1067/msy.2000.107283 (Pubitemid 30623510)
17. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A et al (2001) Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 70:159-164. doi:10.1067/mcp.2001.117444 (Pubitemid 32777768)
18. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ et al (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5:389-392. doi:10.1097/00008571-199512000-00008 (Pubitemid 26010117)
19. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819
20. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 287:1690-1698. doi:10.1001/jama.287.13.1690
21. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547. doi:10.1097/01.fpc.0000114760.08559.dc (Pubitemid 39100005)
22. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM (2004) CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 75:198-203. doi:10.1016/j.clpt.2003.09.015 (Pubitemid 38314869)
23. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719. doi:10.1016/S0140-6736(98) 04474-2 (Pubitemid 29103806)
24. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R (2008) CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 64:9-15. doi:10.1007/s00228-007- 0385-2
25. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847. doi:10.1139/cjpp-79- 10-841 (Pubitemid 33033541)
26. Xie HG, Prasad HC, Kim RB, Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270. doi:10.1016/S0169-409X(02) 00076-5
27. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293. doi:10.1056/NEJMoa044503 (Pubitemid 40740552)
28. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751. doi:10.1093/hmg/ddi180 (Pubitemid 41430097)
29. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93:23-26
30. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541. doi:10.1038/ nature02214 (Pubitemid 38209110)
31. Wajih N, Sane DC, Hutson SM, Wallin R (2005) Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem 280:10540-10547. doi:10.1074/jbc. M413982200 (Pubitemid 40395914)
32. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140. doi:10.1182/blood-2005-01-0341 (Pubitemid 40967184)
33. Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 120:1-10. doi:10.1016/j.thromres.2006.10.021 (Pubitemid 46601582)
34. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112. doi:10.1182/blood-2007-11-122010
35. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI et al (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027. doi:10.1182/blood-2008-01-134247
36. Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a Hu-GEnet systematic review and meta-analysis. Genet Med 7:97-104. doi:10.1097/01.GIM.0000153664.65759.CF (Pubitemid 40261834)
37. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I et al (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3:137-145
38. Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93:700-705
39. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH et al (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84:83-89. doi:10.1038/sj.clpt.6100453 (Pubitemid 351861488)
40. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563-2570. doi:10.1161/CIRCULATIONAHA.107.737312 (Pubitemid 350179221)
41. Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotypeguided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460-470. doi:10.1038/sj.clpt.6100316 (Pubitemid 351272635)
42. Jeffrey S (2002) Atrial fibrillation and stroke-what are the risks? Neurology Reviews.com (March). http://www.neurologyreviews.com/march02/atrial. html. Accessed 19 June 2008
43. Carlquist JF, McKinney JT, Nicholas ZP, Clark JL, Kahn SF, Horne BD et al (2008) Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing. J Thromb Thrombolysis 26:1-7. doi:10.1007/s11239-007-0077-x
44. King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS et al (2008) Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 129:876-883. doi:10.1309/1E34UAPR06PJ6HML
45. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E et al (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110:1511-1515. doi:10.1182/blood-2007-01-069609 (Pubitemid 47443966)
46. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333. doi:10.1182/blood-2005-03-1108 (Pubitemid 41510803)
47. Caldwell MD, Berg R (2008) Case study: warfarin pharmacogenetics from single to multiple genes. In: Roden D (ed) Cardiovascular genetics and genomics, Chapter 16. Blackwell Publishing (in press)
48. Pharm GKB (2008) Genetic determinants of initial warfarin response. Available at http://www.pharmgkb.org/do/serve?objCls=Submission&objId= PS207715. Accessed 28 Aug 2008
49. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ (2005) Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 96:595-598. doi:10.1016/j.amjcard.2005.03.104 (Pubitemid 41132782)
50. Higashi MK, Veenstra DL (2003) Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care 9:493-500
51. McWilliam A, Lutter R, Nardinelli C (2008) Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personalized Med 5:279-284. doi:10.2217/17410541.5.3.279 (Pubitemid 351819084)
52. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B et al (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10:139-150